Anti-Human 4-1BBL (TNFSF9) (Clone CPTC-TNFSF9-1) – Purified No Carrier Protein

TNFSF9 synthetic peptide EGPELSPDDPAGLLDLR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Research Use Only

2 – 8° C Wet Ice

FSAI164R-10H6 activity is directed against TNFSF9 (also known as 4-1BBL).

CPTC-TNFSF9-1

TNFSF9 and TNFRSF9 are a receptor ligand pair belonging to the tumor necrosis factor (TNF) receptor/TNF superfamily^1,2. TNFSF9 is a type II transmembrane protein expressed by activated B cells, macrophages, and dendritic cells^1-5. Members of the TNF-TNF receptor superfamily play critical roles in regulating cellular activation, differentiation, and apoptosis⁶ . TNFSF9/TNFRSF9 interaction is important in cellular immune responses⁵ and provides a co-stimulatory signal to T cells, resulting in increased proliferation and cytokine production⁵. TNFSF9 plays a role in both the inflammatory and cancer microenvironments and is being investigated as a target of cancer immunotherapies⁷. Therapeutic technologies including virus vaccines, a fusion protein composed of tumstatin and TNFSF9, CAR-T, and blockade are being evaluated for their anti- tumor effects.

FSAI164R-10H6 was generated in mouse using a non-modified peptide sequence (EGPELSPDDPAGLLDLR) of human TNFSF9^8,9. FSAI164R-10H6 was developed for use in immuno-MRM assays. FSAI164R-10H6 does not detect TNFSF9 when used to probe Western blots loaded with cell lysates or TNFSF9 recombinant protein¹⁰.

TNFSF9 is expressed on antigen-presenting cells, hematopoietic stem/progenitor cells, and natural killer cells. TNFSF9 is also observed in some solid tumors.

TNFRSF9

1 Goodwin RG, Din WS, Davis-Smith T, et al. Eur. J. Immunol. 23:2631-2641. 1993.
2 Alderson MR, Smith CA, Tough TW, et al. Eur. J. Immunol. 24:2219-2227. 1994.
3 Pollok KE, Kim YJ, Hurtado J, et al. Eur J Immunol. 24(2):367-374. 1994.
4 DeBenedette MA, Shahinian A, Mak TW, et al. J. Immunol. 158:551-559. 1997.
5 Futagawa T, Akiba H, Kodama T, et al. Int Immunol. 14(3):275-286. 2002.
6 Smith CA, Farrah T, Goodwin RG. Cell 76:959-962. 1994.
7 Wu J, Wang Y. Eur J Pharmacol. 928:175097. 2022.
8 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
9 https://research.fredhutch.org/content/dam/stripe/paulovich/files/PaulovichLab_Mab_AvailableForImmuno-MRM_11092020.pdf
10 https://antibodies.cancer.gov/detail/TNFSuperfamilyMember9Peptide1#CPTC-TNFSF9-1-Background